clinical trial · NCT05191680
TherApeutics in Early ProState Cancer (TAPS02)
Cambridge University Hospitals NHS Foundation Trust·phase2·recruiting·n = 90
Prostate CancerApalutamide Oral Tablet [Erleada]Placebo
brief summary
This is a phase 2, randomised, multicentre, double-blind, placebo-controlled trial investigating the use of short term androgen deprivation therapy in the form of apalutamide (Erleada) in men on active surveillance for prostate cancer.
started
Apr 24, 2023
primary completion
Oct 1, 2029
completion
Oct 1, 2029
last updated
Jun 20, 2025
official title
Targeted Drug Intervention in Men at Risk of Progression on Active Surveillance for Early Prostate Cancer: A Randomised Trial - Therapeutics in Active Prostate Cancer Surveillance (TAPS02).
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol